The U.S. gout therapeutics market, valued at USD 1.40 billion in 2024, is anticipated to expand at a CAGR of 6.9% from 2025 to 2034, with growth increasingly driven by segment-wise performance across product types, treatment phases, and therapeutic platforms. The market can be segmented by product type into urate-lowering therapies (ULTs), anti-inflammatory agents, and emerging biologics, with...

  The Europe gout therapeutics market, valued at USD 688.26 million in 2024, is anticipated to expand at a CAGR of 6.8% from 2025 to 2034, with growth increasingly driven by segment-wise performance across product types, treatment phases, and therapeutic platforms. The market can be segmented by product type into urate-lowering therapies (ULTs), anti-inflammatory agents, and emerging...

The U.S. allergy and autoimmune disease diagnostics market, valued at USD 4.24 billion in 2024, is anticipated to expand at a CAGR of 8.5% from 2025 to 2034, with growth increasingly driven by segment-wise performance across product types, end-user applications, and technological platforms. The market can be segmented by product type into immunoassay analyzers, reagent kits, rapid tests, and...